Tumors grow in a microenvironment in which malignant cells entertain intricated relations with stromal and immune cells Both T and B cell anti-tumor immunity are generated in Tertiary Lymphoid Structures adjacent to tumor beds. In situ generated immunity impacts patient’s prognosis and response to immunotherapy.
This webinar is supported by: Thermo Fisher Scientific
The production of this webinar was supported by Thermo Fisher Scientific. Thermo Fisher Scientific has had no influence on the content, and full editorial control remains the sole responsibility of IUIS.
Thermo Fisher Scientific understands your samples are precious in immunology research. Our products and technologies support your wise use of samples to get qualitative and quantitative measurements when evaluating experiments. Our mission is to enable our customers to make the world healthier, cleaner, and safer.
Wolf H. Fridman
Professor Wolf H. Fridman is Professor Emeritus of Immunology at Université Paris Cité, in Paris, France. His research focused on the analysis of the tumor microenvironment. Since 2005, his studies have changed the paradigm of host/cancer interactions by demonstrating that the ‘immune contexture”, taking in account the functionality, the location and the density of the immune infiltrate is the major prognostic factor for human cancers. He has recently demonstrated that Tertiary Lymphoid Structures (TLS), adjacent to tumor beds shape efficient T and B cell immunity, the later resulting in the production of anti-tumor antibodies that impact patient’s prognosis and response to immunotherapy. These findings open the way for novel immune-based tools for efficient prognosis and therapy of cancers.
Rosana Pelayo holds a Principal Investigator position in the Mexican Institute for Social Security, Puebla, Mexico, where she leads the Oncoimmunology Laboratory. Rosana Pelayo is Past-President of the Mexican Society of Immunology and Vice-Chair of the IUIS Education Committee.